The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head‐to‐head study

Abstract

Background: Several studies have demonstrated the efficacy of house dust mite (HDM) immunotherapy in allergic rhinitis (AR). We aimed to compare the efficacy and safety of 2 commercial HDM extracts in a Chinese AR population. Methods:This was an open-label study. HDM-associated AR patients were randomized into Dermatophagoides pteronyssinus (Dp) extracts (Alutard SQ; ALK, Hørsholm, Denmark) and Dp/Dermatophagoides farinae (Df) extracts (NovoHelisen Depot [NHD]; Allergopharma, Reinbek, Germany) groups. All patients received subcutaneous injections for 1 year, and were followed every 3 months during that 1-year period. Symptom score, medication score, and adverse reactions were recorded. The primary endpoint was the total combined symptom and medication score (CSMS) during the efficacy evaluation period. Blood samples were taken for specific immunoglobulin E (IgE), IgG4, and IgE-blocking factor tests at baseline and a er the 1-year treatment.Results: A total of 230 AR patients were randomized; 29 patients dropped out. Analysis of the primary endpoint demonstrated significant reductions in CSMS of 1.8 vs 3.1 (p < 0.001) in the Alutard group and 1.8 vs 3.3 (p < 0.001) in the NHD group compared with baseline. The 2 groups presented equal effectiveness with regard to CSMS, symptom score, and medication score (p > 0.05). The treatment was well tolerated in both groups; 17 (14.8%) patients experienced systemic reactions (SRs) in the Alutard group and 13 (11.3%) in the NHD group. The rates of SRs showed no difference in the 2 groups (p > 0.05), and no anaphylaxis occurred. IgG4 and IgE-blocking factor to Dp and Df were increased significantly in both groups a er the 1-year treatment. Conclusion:Our study confirmed the equal efficacy and safety profile of both commercial extracts in HDMassociated AR patients. C 2019 ARS-AAOA, LLC. et al. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study. Int Forum Allergy Rhinol. 2019;9:876-882.

Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases

“…It is easy to understand that the majority of LRs happened in high dosage HDM extracts (No.4 vial) injection. The incidence of immediate LRs in preschool patients was similar to that observed in patients aged 5-60 years in our previous study [15]. This suggests that SCIT in age below 5 years old group is as tolerable as for children aged above 5 and adults.…”

“…In the confirmed AR children below 6 years old, the sensitization rate of HDM [including Dermatophagoides farina (Df) and Dermatophagoides pteronyssinus (Dp)] was 97.6% [13]. SCIT with commercial HDM extracts of Dp (Alutard SQ, ALK Hørsholm, Denmark) have been demonstrated to be effective in children with AR and/or asthma [14][15][16]. This study aimed to investigate the incidence of side effects and potential risk factors during HDM SCIT in preschool children with respiratory allergy.…”

Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis

“…Khinchi found that the SCIT group had a disease severity reduced to one‐third and the SLIT group to half the severity observed in placebo‐treated 20 . On the contrary, Li's study confirmed the equal efficacy and safety profile of both commercial extracts in HDM‐associated AR patients 21 . Our results suggested that SCIT treatment was more effective compared with SLIT treatment at different time points.…”

“…20 On the contrary, Li's study confirmed the equal efficacy and safety profile of both commercial extracts in HDM-associated AR patients. 21 Our results suggested that SCIT treatment was more effective compared with SLIT treatment at different time points. But the efficacy between the Alutard and NHD groups was comparable.…”

Clinical trial to assess tolerability and subrogate efficacy effects of an abbreviated schedule with house dust mites mixture subcutaneous immunotherapy

“…As a consequence, immunotherapy containing a mixture of DPT and DF is frequently prescribed, although a recent publication did not find differences in efficacy between two commercial mites´ extracts: one with DPT as single source and other with a mixture of DPT and DF (50/50) (24).…”